Tuesday, August 10, 2021, Big Island, Hawaii, 1:00 PM – 3:00 PM HST (7:00 PM – 9:00 PM ET)

Beyond the Guidelines — Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia

Held in Conjunction with the 2021 Pan Pacific Lymphoma Conference

Location
Fairmont Orchid
1 North Kaniku Drive
Kohala Coast, HI 96743
Hotel Phone: (808) 885-2000

Event Schedule (HST)
12:30 PM – 1:00 PM — Registration and Lunch
1:00 PM – 3:00 PM — Symposium

Meeting Room
Grande Ballroom (Lobby Level)


This event will be webcast live.
Please see Registration tab for details.
There is no fee to participate in this satellite symposium program or live webcast of this event. However, in order to attend the in-person event you must be registered for the 2021 Pan Pacific Lymphoma Conference.

Faculty
Alexey V Danilov, MD, PhD
Professor, Department of Hematology and Transplantation
Co-Director, Toni Stephenson Lymphoma Center
City of Hope National Medical Center
Duarte, California

Susan O’Brien, MD
Associate Director for Clinical Science
Medical Director, Sue and Ralph Stern Center for Clinical Trials and Research
Chao Family Endowed Chair for Cancer Clinical Science
Professor, Division of Hematology/Oncology
School of Medicine
UCI Chao Family Comprehensive Cancer Center
Orange, California


Sonali M Smith, MD
Elwood V Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
Co-Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Julie M Vose, MD, MBA
Neumann M and Mildred E Harris Professor
Chief, Hematology/Oncology
University of Nebraska Medical Center
Omaha, Nebraska

Moderator
Matthew S Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and TG Therapeutics Inc.

12:30 PM – 1:00 PM — Registration and Lunch
1:00 PM – 3:00 PM — Symposium

MODULE 1: Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) — Dr O'Brien

  • Published findings from Phase III studies assessing ibrutinib-based therapy for younger and older patients with treatment-naïve CLL
  • Four-year follow-up from the Phase III ELEVATE-TN trial comparing acalabrutinib with and without obinutuzumab to obinutuzumab/chlorambucil for patients with newly diagnosed CLL
  • Implications for therapeutic decision-making of results from the Phase III ELEVATE-RR study of acalabrutinib versus ibrutinib in patients with previously treated high-risk CLL
  • Available data with zanubrutinib in CLL, including recently presented results from the Phase III ALPINE study showing superior response rate, improved progression-free survival and a lower rate of atrial fibrillation/flutter with zanubrutinib compared to ibrutinib in relapsed disease
  • Longer-term efficacy and safety findings from the Phase III CLL14 trial evaluating venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for patients with treatment-naïve CLL
  • Implications, if any, of minimal residual disease assessment (MRD) for the duration of venetoclax-based up-front therapy; current and potential future role of MRD in clinical decision-making

MODULE 2: Spectrum, Frequency, Severity and Management of Toxicities Associated with Novel Agents and Regimens — Dr Smith

  • Incidence and severity of side effects (eg, hemorrhage, atrial fibrillation, infections, cytopenias, hypertension, headache) with Bruton tyrosine kinase (BTK) inhibitors alone and combined with anti-CD20 antibodies
  • Rates of dose reductions, delays and discontinuation with ibrutinib and acalabrutinib; current role of switching BTK inhibitors for treatment-intolerant patients
  • Rates of tumor lysis syndrome among patients with CLL receiving venetoclax-based regimens; recommended protocol for monitoring, prevention and management
  • Spectrum, incidence, severity and management of other toxicities reported with venetoclax-based regimens (eg, neutropenia, infections, gastrointestinal disorders)

MODULE 3: Selection and Sequencing of Therapy for Patients with Relapsed/Refractory (R/R) CLL — Dr Vose

  • Long-term outcomes from Phase III trials evaluating BTK and Bcl-2 inhibitors in patients with R/R CLL
  • Available clinical data with venetoclax reintroduction for patients who experience relapse after completion of limited-duration venetoclax-based therapy
  • Mechanistic similarities and differences among approved PI3 kinase inhibitors; current clinical roles of idelalisib and duvelisib in the CLL treatment paradigm
  • Unique mechanism of action of the PI3K-delta inhibitor umbralisib; efficacy and safety in combination with the anti-CD20 antibody ublituximab in the Phase III UNITY- CLL study

MODULE 4: Novel Strategies Combining BTK and Bcl-2 Inhibitors in CLL — Dr Davids

  • Mechanistic rationale for combining BTK inhibitors, Bcl-2 inhibitors and/or anti-CD20 antibodies in the management of CLL
  • Design, eligibility criteria and major efficacy and safety findings from the Phase III GLOW trial evaluating ibrutinib in combination with venetoclax versus chlorambucil/obinutuzumab for the first-line treatment of CLL; potential implications for clinical practice
  • Depth and duration of response observed in data sets investigating acalabrutinib in combination with venetoclax and an anti-CD20 antibody
  • Incidence and severity of clinically relevant toxicities encountered when combining BTK and Bcl-2 inhibitors with or without anti-CD20 antibodies
  • Ongoing Phase III studies assessing novel doublet and triplet combinations in previously untreated and R/R disease

MODULE 5: Other Promising Investigational Agents and Strategies — Dr Danilov

  • Pharmacologic similarities and differences between covalent and noncovalent BTK inhibitors (eg, pirtobrutinib, ARQ-531); implications for activity and tolerability
  • Efficacy and safety of pirtobrutinib in the Phase I/II BRUIN study; ongoing investigation and potential clinical role
  • Biologic rationale for and early clinical trial experience with CD19-directed chimeric antigen receptor (CAR) T-cell therapy in CLL
  • Eligibility criteria for and primary and secondary endpoints of the Phase I/II TRANSCEND CLL 004 trial assessing lisocabtagene maraleucel in R/R CLL; key findings in the overall trial population and among double-refractory patients
  • Other promising agents and strategies under investigation in CLL

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
At the conclusion of this activity, participants should be able to

  • Individualize the selection of systemic therapy for newly diagnosed CLL, considering clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to evaluate and select available options.
  • Appraise available and recently presented Phase III data documenting the comparative efficacy and tolerability of first- and second-generation BTK inhibitors, and consider the implications of these findings for clinical decision-making for patients with newly diagnosed or previously treated CLL.
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and appropriately integrate this regimen into current treatment decision-making.
  • Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented Phase III data documenting the safety and efficacy of this strategy in patients with newly diagnosed CLL.
  • Analyze how patient age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for relapsed/refractory CLL.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for CLL.
  • Recall available and emerging data with other novel agents, combinations and strategies currently under investigation in CLL, and appropriately refer eligible patients for trial participation.

Accreditation Statement
In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS: The University of Nebraska Medical Center designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES: The University of Nebraska Medical Center designates this activity for 2 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Credit Form
A credit form will be given to each participant.

In order to receive credit, attendees must check in at registration and turn in a completed credit form at the conclusion of the activity. Credit certificates will be issued directly to attendees by UNMC CCE within 4 to 6 weeks after the symposium.

Disclosure Information
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

Disclosures
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:

FACULTY
Alexey V Danilov, MD, PhDAdvisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Karyopharm Therapeutics, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, MEI Pharma Inc, Secura Bio, Takeda Oncology, TG Therapeutics Inc, Verastem Inc. Susan O’Brien, MDConsulting Agreements: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, Aptose Biosciences Inc, Astellas, Autolus, Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Juno Therapeutics, a Celgene Company, Lilly, Merck, NOVA Research Company, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc, Vaniam Group, Verastem Inc, Vida Ventures; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Caribou Biosciences Inc, Gilead Sciences Inc, Kite, A Gilead Company, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc. Sonali M Smith, MDConsulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, MorphoSys, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Novartis, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc. Julie M Vose, MD, MBAAdvisory Committee: AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Conjuro, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, MorphoSys, Oncternal Therapeutics, Roche Laboratories Inc, Umoja Biopharma; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Epizyme Inc, Incyte Corporation, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Seagen Inc; Data and Safety Monitoring Board/Committee: MEI Pharma Inc.

MODERATORMatthew S Davids, MD, MMScAdvisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc.

THE UNIVERSITY OF NEBRASKA MEDICAL CENTER (UNMC) and RESEARCH TO PRACTICE (RTP) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — The below planning committee members have nothing to disclose: Neil Love, MD — RTP President and Planner, Atif Hussein, MD — RTP Reviewer, Renee Paulin, MSN, RN, CWOCN — UNMC Planner and Reviewer, Brenda Ram, CMP, CHCP — UNMC Planner, Michele Williams, DNP, AGPCNP-BC — RTP Reviewer, and Kathryn Ault Ziel, PhD — RTP Staff and Planner.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and TG Therapeutics Inc.

Location
Fairmont Orchid
1 North Kaniku Drive
Kohala Coast, HI 96743
Hotel Phone: (808) 885 2000

Meeting Room
Grande Ballroom (Lobby Level)

Directions
The Fairmont Orchid is the host hotel for the 2021 Pan Pacific Lymphoma Conference.

 
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.

There is no fee to participate in this satellite symposium program or live webcast of this event.

Registration for in-person symposium

In order to attend the in-person symposia event you must be registered for the 2021 Pan Pacific Lymphoma Conference.

Registration for symposium »
 
Registration for live broadcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.